Clinical trial · Interventional
Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer
Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Prostate Cancer Without an Endorectal Coil
NCT05055843CI-TRIAL-00108266active not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial studies examines a 3D magnetic resonance imaging (MRI) compared to standard MRI imaging techniques in screening patients with prostate cancer. Diagnostic procedures, such as MRI, may help find and diagnose prostate cancer. Computer systems that allow doctors to create a 3-dimensional (3-D) picture of the tumor may help in planning.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Adenocarcinoma | Prostate Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Prostate Carcinoma | Prostate Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Magnetic Resonance Imaging | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Screening (3D MRI)
- description
- Patients undergo 3D MRI imaging over 15 minutes with standard of care MRI or at a separate time.
- interventionNames
- Procedure: Magnetic Resonance Imaging
Primary outcomes (1)
- measure
- To be assessed with scoring of quantitative image metrics in regions of prostate cancer and benign tissue
- timeFrame
- through study completion, an average of 1 year
- description
- Comparing the 2-dimensional (2D) T2W imaging technique without endorectal coil. Scored from 1 to 5 with PI-RADS 1 indicating that csPCa is highly unlikely whereas a PI-RADS 5 score indicates that csPCa is highly likely to be present.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male, age \>= 18 * Untreated, biopsy-proven with intermediate and high-risk adenocarcinoma of the prostate * Patient is being considered for curative-intent treatment with radical prostatectomy * Patient has provided written informed consent for participation in this trial * Patient should be eligible for scanning on a 3T magnet Exclusion Criteria: * Low-risk adenocarcinoma of prostate * Any prior therapy for prostate cancer * A history of other active malignancy within the last 2 years * Prostate cancer with significant sarcomatoid, spindle cell, or neuroendocrine small cell components * Cardiac pacemaker * Orthopedic hardware in the pelvis and spine * Claustrophobia
References
Publications (0)
Data not yet available
No reference posted for this study.